



# Addendum to Genome Canada's Corporate Plan 2012–13

## 1. ABOUT THIS DOCUMENT

---

The *Addendum to the Corporate Plan 2012-13* has been prepared in compliance with the terms and conditions stated in the Contribution Agreement of December 2012 between Genome Canada and Industry Canada which states:

*"By December 31, 2012, Genome Canada shall provide to the Minister an addendum to the 2012-13 Corporate Plan. This addendum shall provide the information required by Section 13.6 with respect to the Contribution. Information relating to the Contribution shall be included in all future Corporate Plans."*

The information in this document outlines planned activities for new programs which will be implemented in 2013-14 as a result of the Government of Canada's 2012 federal budget announcement of \$60 million of new funding to Genome Canada. These plans align with Genome Canada's four strategic objectives as stated in Genome Canada's strategic plan, and are reflective of the Board of Directors' decisions to allocate funding to strategic priorities which will deliver social and economic benefits to Canadians:

(Four Strategic Objectives)

- Respond to societal needs by generating genomics discoveries and accelerating their translation into applications
- Attract greater investment in genomics research from a broad range of stakeholders, in particular the private sector
- Enhance the impact of genomics by transforming knowledge of the ethical, environmental, economic, legal and social challenges and opportunities into sound policies and practices
- Enhance the recognition of the value of genomics by increasing stakeholder appreciation of genome science, its applications and implications

## 2. AMENDMENT TO SECTION IV - *Plans for 2012-13*

---

In 2012-13, Genome Canada will continue to focus on designing programs and activities that translate research discoveries into new applications that can lead to economic or social benefits to society, and continue to fund large-scale research projects and support cutting-edge technology. It will focus its efforts in select sectors of strategic importance to Canada – agriculture, environment, fisheries, forestry, health, energy and mining. It will continue to conduct ongoing monitoring and interim reviews of its large-scale research projects and S&T Innovation Centres in order to ensure progress against objectives as well as the meeting of agreed-to milestones. It will continue to consult and engage its research community and other stakeholders with respect to assessing and staying apprised of international developments in science and research. Genome Canada commits to seek out opportunities to leverage the Government of Canada's investment beyond the 1:1 ratio, through the development of partnerships and collaborations. Working in concert with the six Genome Centres, Genome Canada will continue its leadership role in cultivating the complex and collaborative network of individuals and organizations representing the *Canadian Genomics Enterprise*

In addition to those activities outlined in the Corporate Plan 2012-13 which are currently supported through funding commitments from previous funding agreements, the infusion of a Contribution of \$60 million from the Government of Canada will be allocated as follows:

	(in millions of \$)
Large-Scale Applied Projects	
Genomic Application Partnership Program	26.0
Access to Leading-Edge Technology	
Support of Science & Technology Innovation Centres (2013-15)	29.0
Partnerships	
Structural Genomics Consortium (SGC)	2.5
International Barcode of Life (iBOL)	2.5
<b>Total</b>	<b>60.0</b>

The above allocations were approved by Genome Canada's Board of Directors at their September 2012 meeting, with implementation pending the final execution of the funding agreement between Genome Canada and the Government of Canada.

- **Genomic Application Partnership Program (GAPP)** — A total of \$26 million in funding from the \$60 million announced in the Government of Canada's 2012 federal budget will be allocated to the GAPP, an academic-industry partnered program designed to:
  - increase the socio-economic value of genomics by accelerating the translation of genomics research to application or market;
  - promote the development of genomics-based solutions to address key challenges facing industry and end users;
  - create and foster a more productive interface between the public and private sectors; and,
  - promote commercialization and help mitigate risk for future investment from public and private investors.

A working group of the Board of Directors was established by the Board of Directors in June 2012 to oversee the development of this program. To-date, principles and parameters for this program have been reviewed and approved by the board. The intent will be to launch this program in spring 2013.

Anticipated outcomes of this program include:

- Increased engagement of industry partners;
- Increase in research partnerships between academia and the private sector to stimulate Canadian innovation;
- Increase in socio-economic value of genomics research by promoting application of research results;
- Increased level of investment by others;
- Increase in prototypes or early stage products, tools or processes developed and moved closer to the market or application;
- Increase in the level of recognition by sector leaders of the importance of genomics to their sector;
- Increased number of new receptors/end users involved; and,
- Increased uptake of genomics research into policy and practice.

- **The Science and Technology Innovation Centres (STICs)** — A total of \$29 million in funding from the \$60 million announced in the Government of Canada's 2012 federal budget will be allocated to support the five current STICs until March 31, 2015. This funding support will allow for:
- the continuation of the essential services provided by the current 5 STICs offered to the public and private sectors, relating to areas such as genomics, proteomics, metabolomics, and bioinformatics;
  - development of cutting edge genomics-based technologies to ensure their international competitiveness;
  - support of networking activities that promote the STICs to work together more cooperatively;
  - acquisition of new equipment to increase operational efficiencies and remain at the cutting edge; and,
  - retention of top scientists in Canada as leaders of the STICs.

The allocation of continued funding to support the STICs for an additional two years will be done via a renewal process which will involve an international committee of experts. This process will provide assurance that the existing STICs are providing leading edge technologies and methods in a competitive manner; and, that there are sufficient resources to manage and analyze the significant amount of data generated by the high throughput technologies. Funding will be provided for core operating support; technology development; and, purchase of equipment. In addition, funding will be used to sustain national STICs networking activities, designed to promote collaboration among and between STICs.

▶ **The Structural Genomics Consortium (SGC)** — The SGC is an international public-private partnership launched in 2004 that supports the discovery of new medicines through open-accessed research. Its core mandate is to determine the three dimensional structures of proteins of therapeutic importance to humans and place them in the public domain without restriction on their use. The SGC is viewed as “the model for the future of early stage discovery and public-private partnerships”.

Phase III of the SGC began July 1, 2011. A total of \$67.7 million has now been committed to Phase III by funding partners, of which \$28.7 million is from the public sector (including \$2.5 million for one year from Genome Canada ending June 30, 2012) and \$39 million from the private sector, including GSK, Pfizer, Novartis, Lilly, Life Technologies, Abbott Laboratories, Takeda Pharmaceuticals, Boehringer Ingelheim and J&J. In addition, SGC has secured at least \$8M of in-kind support from pharmaceutical companies.

A total of \$2.5 million in funding from the \$60 million announced in the Government of Canada's 2012 federal budget will be allocated to sustain the Canadian operational activities portion of the SGC.

▶ **The International Barcode of Life (iBOL) Project**—The iBOL, established in 2009, is the largest biodiversity genomics initiative ever undertaken. Over 250 researchers from 25 countries are working together to construct a DNA barcode reference library that will be the foundation for a rapid and inexpensive DNA-based identification system for all multi-cellular life. In the first phase of operations (2009-2015), iBOL collaborators plan to barcode five million specimens representing 500,000 species. The resource being generated by iBOL, enables many practical and commercial opportunities related to health, trade, environment, and agri-food, providing significant benefits to Canada.

A total of \$2.5 million in funding from the \$60 million announced in the Government of Canada's 2012 federal budget was approved for an additional year of funding support toward the consortium's activities.

**GENOME CANADA**  
**Forecast Cash Disbursements for Investment of \$60 Million**

*( In Millions of Dollars )*

	12-13	13-14	14-15	15-16	16-17	Total
<b>STICs</b>		\$13.0	\$16.0			<b>\$29.0</b>
<b>GAPP</b>		\$1.0	\$8.0	\$10.0	\$7.0	<b>\$26.0</b>
<b>iBOL</b>	\$1.9	\$0.6				<b>\$2.5</b>
<b>SGC</b>	\$1.9	\$0.6				<b>\$2.5</b>
<b>Total Genome Canada</b>	<b>\$3.8</b>	<b>\$15.2</b>	<b>\$24.0</b>	<b>\$10.0</b>	<b>\$7.0</b>	<b>\$60.0</b>
<b>Total Co-Funding</b>						<b>\$61.0</b>
<b>Total Investment</b>						<b>\$121.0</b>